首页 > 最新文献

Acta Pharmaceutica最新文献

英文 中文
The impact of cryoprotectant exposure time on post-thaw viability of autologous and allogeneic hematopoietic stem cells and leukocyte subpopulations. 低温保护剂暴露时间对自体和异体造血干细胞及白细胞亚群解冻后存活率的影响。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0037
Vladimira Rimac, Ines Bojanić, Sanja Dabelić, Branka Golubić Ćepulić

Although the use of cryoprotectant dimethyl sulfoxide (DMSO) is the gold standard in cryopreservation of hematopoietic stem cells, it is well known that it has a negative effect on cell viability. The aim of this prospective study was to examine how the length of post-thaw exposure to DMSO affects the cell viability and stability of peripheral blood stem cell (PBSC) samples. Additionally, the effects of donor type and pre-cryopreservation storage time on post-thaw viability during the stability study were evaluated. In 30 autologous and 30 allogeneic PBSC samples viable CD34+, CD14+, CD19+, CD16+/56+, and CD3+ cells were determined immediately after thawing, and one-and three-hours post-thaw. Analysis of the absolute count of viable cells in thawed samples showed a significant difference between all measurement points for CD34+ (p < 0.001), CD14+ (p < 0.001), and CD19+ cells (p < 0.001). No significant differences were observed for post-thaw stability of allogeneic samples analysed between products stored before cryopreservation ≥ 24 hours (N = 20), and those stored < 24 hours (N = 10), except for viable CD3+/CD4+ cells after three hours post-thaw (p = 0.028). In conclusion, DMSO had different effects on leukocyte subpopulations in cryopre-served PBSC samples. The type of donors and the length of storage before cryopreservation did not affect the post-thaw stability of cryopreserved PBSC samples.

尽管使用低温保护剂二甲基亚砜(DMSO)是低温保存造血干细胞的黄金标准,但众所周知,它对细胞存活率有负面影响。这项前瞻性研究旨在探讨解冻后暴露于二甲基亚砜的时间长短如何影响外周血干细胞(PBSC)样本的细胞活力和稳定性。此外,在稳定性研究中,还评估了供体类型和冷冻保存前储存时间对解冻后存活率的影响。在 30 份自体和 30 份异体 PBSC 样本中,分别测定了解冻后立即存活的 CD34+、CD14+、CD19+、CD16+/56+ 和 CD3+ 细胞,以及解冻后 1 小时和 3 小时的存活细胞。对解冻样本中存活细胞绝对计数的分析表明,CD34+细胞(p < 0.001)、CD14+细胞(p < 0.001)和CD19+细胞(p < 0.001)在所有测量点之间都有显著差异。除了解冻后 3 小时后存活的 CD3+/CD4+ 细胞外(p = 0.028),分析的同种异体样本解冻后稳定性在冷冻保存前储存时间≥ 24 小时的样本(N = 20)和储存时间< 24 小时的样本(N = 10)之间无明显差异。总之,DMSO 对冷冻保存的 PBSC 样本中的白细胞亚群有不同的影响。供体类型和冷冻保存前的储存时间并不影响冷冻保存的 PBSC 样本在解冻后的稳定性。
{"title":"The impact of cryoprotectant exposure time on post-thaw viability of autologous and allogeneic hematopoietic stem cells and leukocyte subpopulations.","authors":"Vladimira Rimac, Ines Bojanić, Sanja Dabelić, Branka Golubić Ćepulić","doi":"10.2478/acph-2023-0037","DOIUrl":"10.2478/acph-2023-0037","url":null,"abstract":"<p><p>Although the use of cryoprotectant dimethyl sulfoxide (DMSO) is the gold standard in cryopreservation of hematopoietic stem cells, it is well known that it has a negative effect on cell viability. The aim of this prospective study was to examine how the length of post-thaw exposure to DMSO affects the cell viability and stability of peripheral blood stem cell (PBSC) samples. Additionally, the effects of donor type and pre-cryopreservation storage time on post-thaw viability during the stability study were evaluated. In 30 autologous and 30 allogeneic PBSC samples viable CD34+, CD14+, CD19+, CD16+/56+, and CD3+ cells were determined immediately after thawing, and one-and three-hours post-thaw. Analysis of the absolute count of viable cells in thawed samples showed a significant difference between all measurement points for CD34+ (<i>p</i> < 0.001), CD14+ (<i>p</i> < 0.001), and CD19+ cells (<i>p</i> < 0.001). No significant differences were observed for post-thaw stability of allogeneic samples analysed between products stored before cryopreservation ≥ 24 hours (N = 20), and those stored < 24 hours (N = 10), except for viable CD3+/CD4+ cells after three hours post-thaw (<i>p</i> = 0.028). In conclusion, DMSO had different effects on leukocyte subpopulations in cryopre-served PBSC samples. The type of donors and the length of storage before cryopreservation did not affect the post-thaw stability of cryopreserved PBSC samples.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"655-672"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia. 克罗地亚早期乳腺癌幸存者对药物的信念与坚持内分泌治疗的关系。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0043
Ana Dugonjić Okroša, Tajana Silovski, Natalija Dedić Plavetić, Hrvoje Silovski, Ana Kovačić, Iva Mucalo

This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients' beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence and sociodemographic and clinical factors. Out of 420 early breast cancer (BC) patients included in the study, 79.5 % perceived AET necessary and important for their health, as measured by the Belief About Medicines Questionnaire (BMQ), with the mean necessity score (20.4 ± 3.68) significantly higher than the mean concerns score (13 ± 4.81) (p < 0.001). Based on the Medication Adherence Report Scale (MARS-5), 44.4 % (n = 182) of the participants were non-adherers, out of which 63.2 % (n = 115) were unintentional and 36.8 % (n = 67) intentional non-adherers. Significantly higher concern beliefs were found among patients that were younger (p < 0.001), employed (p < 0.001), intentionally non-adherent to AET (p = 0.006), had a lower body-mass index (p = 0.005) and a higher level of education (p < 0.001), were premenopausal at the time of diagnosis (p < 0.001), taking tamoxifen treatment (p = 0.05) and receiving ovarian suppression (p < 0.001). Younger patients should be recognized as being at risk of non-adherence as they hold greater concern beliefs about medicines.

这项观察性横断面研究在萨格勒布大学医院中心(UHC Zagreb)进行,旨在探讨患者对辅助内分泌治疗(AET)的信念及其与不依从性、社会人口学和临床因素的关系。在参与研究的420名早期乳腺癌(BC)患者中,79.5%的患者认为辅助内分泌治疗对其健康是必要且重要的,这是由 "对药物的信念问卷"(BMQ)测量得出的结果,其中必要性的平均得分(20.4 ± 3.68)明显高于关注的平均得分(13 ± 4.81)(P < 0.001)。根据用药依从性报告量表(MARS-5),44.4%(n = 182)的参与者为不依从者,其中 63.2%(n = 115)为无意不依从者,36.8%(n = 67)为有意不依从者。年轻(p < 0.001)、有工作(p < 0.001)、有意不坚持 AET(p = 0.006)、体重指数较低(p = 0.005)、受教育程度较高(p < 0.001)、确诊时绝经前(p < 0.001)、服用他莫昔芬(p = 0.05)和接受卵巢抑制(p < 0.001)的患者的担忧信念明显较高。应认识到年轻患者有可能不坚持用药,因为他们对药物抱有更多的担忧。
{"title":"Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia.","authors":"Ana Dugonjić Okroša, Tajana Silovski, Natalija Dedić Plavetić, Hrvoje Silovski, Ana Kovačić, Iva Mucalo","doi":"10.2478/acph-2023-0043","DOIUrl":"10.2478/acph-2023-0043","url":null,"abstract":"<p><p>This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients' beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence and sociodemographic and clinical factors. Out of 420 early breast cancer (BC) patients included in the study, 79.5 % perceived AET necessary and important for their health, as measured by the Belief About Medicines Questionnaire (BMQ), with the mean necessity score (20.4 ± 3.68) significantly higher than the mean concerns score (13 ± 4.81) (<i>p</i> < 0.001). Based on the Medication Adherence Report Scale (MARS-5), 44.4 % (<i>n</i> = 182) of the participants were non-adherers, out of which 63.2 % (<i>n</i> = 115) were unintentional and 36.8 % (<i>n</i> = 67) intentional non-adherers. Significantly higher concern beliefs were found among patients that were younger (<i>p</i> < 0.001), employed (<i>p</i> < 0.001), intentionally non-adherent to AET (<i>p</i> = 0.006), had a lower body-mass index (<i>p</i> = 0.005) and a higher level of education (<i>p</i> < 0.001), were premenopausal at the time of diagnosis (<i>p</i> < 0.001), taking tamoxifen treatment (<i>p</i> = 0.05) and receiving ovarian suppression (<i>p</i> < 0.001). Younger patients should be recognized as being at risk of non-adherence as they hold greater concern beliefs about medicines.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"673-689"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, antiproliferative and antiplasmodial evaluation of new chloroquine and mefloquine-based harmiquins. 以氯喹和甲氟喹为基础的新型喹螨醚的合成、抗增殖性和抗疟性评价。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0035
Kristina Pavić, Goran Poje, Lais Pessanha De Carvalho, Jana Held, Zrinka Rajić

Here we present the synthesis and evaluation of the biological activity of new hybrid compounds, ureido-type (UT) harmiquins, based on chloroquine (CQ) or mefloquine (MQ) scaffolds and β-carboline alkaloid harmine against cancer cell lines and Plasmodium falciparum. The hybrids were prepared from the corresponding amines by 1,1'-carbonyldiimidazole (CDI)-mediated synthesis. In vitro evaluation of the biological activity of the title compounds revealed two hit compounds. Testing of the antiproliferative activity of the new UT harmiquins, and previously prepared triazole-(TT) and amide-type (AT) CQ-based harmiquins, against a panel of human cell lines, revealed TT harmiquine 16 as the most promising compound, as it showed pronounced and selective activity against the tumor cell line HepG2 (IC 50 = 5.48 ± 3.35 μmol L-1). Screening of the antiplasmodial activities of UT harmiquins against erythrocytic stages of the Plasmodium life cycle identified CQ-based UT harmiquine 12 as a novel antiplasmodial hit because it displayed low IC 50 values in the submicromolar range against CQ-sensitive and resistant strains (IC 50 0.06 ± 0.01, and 0.19 ± 0.02 μmol L-1, respectively), and exhibited high selectivity against Plasmodium, compared to mammalian cells (SI = 92).

在此,我们介绍了基于氯喹(CQ)或甲氟喹(MQ)支架和 β-咔啉生物碱 harmine 的新杂交化合物尿苷型(UT)噻喹酮的合成及其对癌细胞株和恶性疟原虫生物活性的评估。这些混合物由相应的胺通过 1,1'-羰基二咪唑(CDI)介导的合成制备而成。在对标题化合物的生物活性进行体外评估时,发现了两个命中化合物。通过测试新的UT harmiquins以及之前制备的三唑类(TT)和酰胺类(AT)CQ harmiquins对人类细胞系的抗增殖活性,发现TT harmiquine 16是最有前途的化合物,因为它对肿瘤细胞系HepG2具有明显的选择性活性(IC 50 = 5.48 ± 3.35 μmol L-1)。通过筛选UT harmiquins 对疟原虫生命周期中红细胞阶段的抗疟活性,发现基于 CQ 的UT harmiquine 12 是一种新型抗疟新药,因为它对 CQ 敏感和耐药菌株的 IC 50 值很低,在亚微摩范围内(IC 50 分别为 0.06 ± 0.01 和 0.19 ± 0.02 μmol L-1),而且与哺乳动物细胞相比,它对疟原虫具有很高的选择性(SI = 92)。
{"title":"Synthesis, antiproliferative and antiplasmodial evaluation of new chloroquine and mefloquine-based harmiquins.","authors":"Kristina Pavić, Goran Poje, Lais Pessanha De Carvalho, Jana Held, Zrinka Rajić","doi":"10.2478/acph-2023-0035","DOIUrl":"10.2478/acph-2023-0035","url":null,"abstract":"<p><p>Here we present the synthesis and evaluation of the biological activity of new hybrid compounds, ureido-type (UT) harmiquins, based on chloroquine (CQ) or mefloquine (MQ) scaffolds and β-carboline alkaloid harmine against cancer cell lines and <i>Plasmodium falciparum</i>. The hybrids were prepared from the corresponding amines by 1,1'-carbonyldiimidazole (CDI)-mediated synthesis. <i>In vitro</i> evaluation of the biological activity of the title compounds revealed two hit compounds. Testing of the antiproliferative activity of the new UT harmiquins, and previously prepared triazole-(TT) and amide-type (AT) CQ-based harmiquins, against a panel of human cell lines, revealed TT harmiquine <b>16</b> as the most promising compound, as it showed pronounced and selective activity against the tumor cell line HepG2 (<i>IC</i> <sub>50</sub> = 5.48 ± 3.35 μmol L<sup>-1</sup>). Screening of the antiplasmodial activities of UT harmiquins against erythrocytic stages of the <i>Plasmodium</i> life cycle identified CQ-based UT harmiquine <b>12</b> as a novel antiplasmodial hit because it displayed low <i>IC</i> <sub>50</sub> values in the submicromolar range against CQ-sensitive and resistant strains (<i>IC</i> <sub>50</sub> 0.06 ± 0.01, and 0.19 ± 0.02 μmol L<sup>-1</sup>, respectively), and exhibited high selectivity against <i>Plasmodium</i>, compared to mammalian cells (SI = 92).</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"537-558"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of epidurally administered dexmedetomidine and dexamethasone on postoperative pain, analgesic requirements, inflammation, and oxidative stress in thoracic surgery. 硬膜外注射右美托咪定和地塞米松对胸外科术后疼痛、镇痛需求、炎症和氧化应激的影响。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0040
Jasminka Peršec, Andrej Šribar, Monika Ilić, Ivan Mamić, Domagoj Kifer, Ana-Marija Domijan, Željan Maleš, Petra Turčić

The aim of this study was to compare the effects of dexmedetomidine and dexamethasone as adjuvants to preoperative epidural administration of local anesthetic (ropivacaine) in thoracic surgery on the postoperative level of pain, use of analgesics, inflammation, and oxidative stress. The study enrolled 42 patients who underwent elective thoracic surgery in a one-year period at the University Hospital Dubrava (Zagreb, Croatia). Based on a computer-generated randomization list the patients were assigned to the dexmedetomidine (n = 18) or dexamethasone (n = 24) group. Postoperatively, patients of dexmedetomidine group reported lower pain (VAS value 1 h post surgery, 3.4 ± 2.7 vs. 5.4 ± 1.8, dexmedetomidine vs. dexamethasone, p < 0.01) and had lower anal-gesic requirements in comparison with dexamethasone group. Thus, dexmedetomidine in comparison with dexamethasone was more efficient in lowering pain and analgesia requirements 24 h after the surgery. On the contrary, dexamethasone had better anti-inflammatory properties (CRP level 24 h post surgery, 131.9 ± 90.7 vs. 26.0 ± 55.2 mg L-1, dexmedetomidine vs. dexamethasone, p < 0.01). Both dexmedetomidine and dexamethasone exhibited antioxidant effects, however, their antioxidant properties should be further explored. The results of this study improve current knowledge of pain control in thoracic surgery.

本研究旨在比较右美托咪定和地塞米松作为胸外科手术术前硬膜外注射局麻药(罗哌卡因)的辅助用药对术后疼痛程度、镇痛药使用、炎症和氧化应激的影响。该研究共招募了 42 名患者,他们在一年内接受了杜布拉瓦大学医院(克罗地亚萨格勒布)的择期胸外科手术。根据计算机生成的随机名单,患者被分配到右美托咪定组(18 人)或地塞米松组(24 人)。与地塞米松组相比,右美托咪定组患者术后疼痛较轻(术后1小时VAS值,3.4 ± 2.7 vs. 5.4 ± 1.8,右美托咪定 vs. 地塞米松,p < 0.01),肛门镇痛需求也较低。因此,与地塞米松相比,右美托咪定能更有效地降低术后24小时的疼痛和镇痛需求。相反,地塞米松具有更好的抗炎特性(术后 24 小时 CRP 水平,131.9 ± 90.7 vs. 26.0 ± 55.2 mg L-1,右美托咪定 vs. 地塞米松,p < 0.01)。右美托咪定和地塞米松都具有抗氧化作用,但它们的抗氧化特性还需进一步研究。本研究的结果提高了目前对胸外科疼痛控制的认识。
{"title":"Effects of epidurally administered dexmedetomidine and dexamethasone on postoperative pain, analgesic requirements, inflammation, and oxidative stress in thoracic surgery.","authors":"Jasminka Peršec, Andrej Šribar, Monika Ilić, Ivan Mamić, Domagoj Kifer, Ana-Marija Domijan, Željan Maleš, Petra Turčić","doi":"10.2478/acph-2023-0040","DOIUrl":"10.2478/acph-2023-0040","url":null,"abstract":"<p><p>The aim of this study was to compare the effects of dexmedetomidine and dexamethasone as adjuvants to preoperative epidural administration of local anesthetic (ropivacaine) in thoracic surgery on the postoperative level of pain, use of analgesics, inflammation, and oxidative stress. The study enrolled 42 patients who underwent elective thoracic surgery in a one-year period at the University Hospital Dubrava (Zagreb, Croatia). Based on a computer-generated randomization list the patients were assigned to the dexmedetomidine (<i>n</i> = 18) or dexamethasone (<i>n</i> = 24) group. Postoperatively, patients of dexmedetomidine group reported lower pain (VAS value 1 h post surgery, 3.4 ± 2.7 <i>vs.</i> 5.4 ± 1.8, dexmedetomidine <i>vs.</i> dexamethasone, <i>p</i> < 0.01) and had lower anal-gesic requirements in comparison with dexamethasone group. Thus, dexmedetomidine in comparison with dexamethasone was more efficient in lowering pain and analgesia requirements 24 h after the surgery. On the contrary, dexamethasone had better anti-inflammatory properties (CRP level 24 h post surgery, 131.9 ± 90.7 <i>vs.</i> 26.0 ± 55.2 mg L<sup>-1</sup>, dexmedetomidine <i>vs.</i> dexamethasone, <i>p</i> < 0.01). Both dexmedetomidine and dexamethasone exhibited antioxidant effects, however, their antioxidant properties should be further explored. The results of this study improve current knowledge of pain control in thoracic surgery.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"691-708"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mendeleev's discovery of the periodic table and the first European Academy of Sciences to honour him. 门捷列夫发现元素周期表,欧洲科学院首次向他致敬。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0039
Vanja Horvat Flegar, Suzana Inić

The chemical science community will commemorate the 155th anniversary of Mendeleev's groundbreaking discovery of the periodic table of elements in 2024. This paper aims to underscore the significance of Mendeleev's honorary membership in the Academy of Sciences in Zagreb, Croatia, which occurred in 1882, making it the first scientific academy in Europe to extend this recognition. Additionally, we seek to explore the contextual circumstances that contributed to this noteworthy event within the broader European context. To provide insight into the specificities and variations in the influence and reception of the periodic table of elements within the educational process of select European countries (Russia, Germany, Czech Lands, Serbia), we conducted a comprehensive review, drawing comparisons to Croatia. Notably, upon its initial publication in 1869, the discovery of the periodic table did not gain immediate acceptance in Croatia, largely attributed to the absence of a well-established presence of chemical science within the country. About fifteen years passed from Mendeleev's discovery of the periodic law to its reception and dissemination throughout Croatia. Despite an initial delay, Croatian chemical science followed the development of the periodic table through secondary and university education, while actively partaking it in.

化学科学界将于 2024 年纪念门捷列夫开创性地发现元素周期表 155 周年。本文旨在强调门捷列夫于 1882 年成为克罗地亚萨格勒布科学院荣誉院士的重要意义,该科学院是欧洲第一个授予门捷列夫荣誉院士称号的科学院。此外,我们还试图在更广泛的欧洲背景下探讨促成这一值得注意的事件的背景情况。为了深入了解元素周期表在部分欧洲国家(俄罗斯、德国、捷克、塞尔维亚)教育过程中的影响和接受情况的特殊性和差异,我们进行了一次全面回顾,并与克罗地亚进行了比较。值得注意的是,元素周期表于 1869 年首次公布后,并没有立即在克罗地亚得到接受,这在很大程度上归因于该国缺乏完善的化学科学。从门捷列夫发现周期律到克罗地亚接受和传播周期律大约经历了 15 年的时间。尽管起初有所延误,但克罗地亚化学科学界通过中学和大学教育一直关注着周期表的发展,同时也积极参与其中。
{"title":"Mendeleev's discovery of the periodic table and the first European Academy of Sciences to honour him.","authors":"Vanja Horvat Flegar, Suzana Inić","doi":"10.2478/acph-2023-0039","DOIUrl":"10.2478/acph-2023-0039","url":null,"abstract":"<p><p>The chemical science community will commemorate the 155<sup>th</sup> anniversary of Mendeleev's groundbreaking discovery of the periodic table of elements in 2024. This paper aims to underscore the significance of Mendeleev's honorary membership in the Academy of Sciences in Zagreb, Croatia, which occurred in 1882, making it the first scientific academy in Europe to extend this recognition. Additionally, we seek to explore the contextual circumstances that contributed to this noteworthy event within the broader European context. To provide insight into the specificities and variations in the influence and reception of the periodic table of elements within the educational process of select European countries (Russia, Germany, Czech Lands, Serbia), we conducted a comprehensive review, drawing comparisons to Croatia. Notably, upon its initial publication in 1869, the discovery of the periodic table did not gain immediate acceptance in Croatia, largely attributed to the absence of a well-established presence of chemical science within the country. About fifteen years passed from Mendeleev's discovery of the periodic law to its reception and dissemination throughout Croatia. Despite an initial delay, Croatian chemical science followed the development of the periodic table through secondary and university education, while actively partaking it in.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"735-753"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors. 探索晚期乳腺癌患者的依从性:关注 CDK4/6 抑制剂。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0045
Matea Baković, Martina Bago, Lucija Benić, Magdalena Krajinović, Tajana Silovski, Natalija Dedić Plavetić, Lu Turković, Miranda Sertić, Maja Ortner Hadžiabdić

Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, i.e. patients' attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to explore the adherence to oral anticancer medications (OAM) in women with advanced breast cancer, focusing on cyclin-dependent kinase 4 and 6 inhibitors (CDKI), and identify factors associated with the adherence. We conducted a cross-sectional study at the University Hospital Centre Zagreb, Croatia, involving women with stage IV advanced breast cancer receiving OAM. Data collection included a questionnaire assessing socio-demographic and clinical information, Beck Depression Inventory-II for depressive symptoms, Medication Adherence Report Scale (MARS-5) for adherence to OAM, and Beliefs about Medicines Questionnaire. Plasma concentrations of CDKI were confirmed by LC-MS/MS in three randomly selected participants. A total of 89 women were included. The most prescribed OAMs were anti-estrogen (71.3 %) and CDKI (60.9 %). MARS-5 scores (mean: 24.1 ± 1.6) correlated with CDKI plasma concentrations. Forgetfulness was the primary reason for non-adherence (25.9 %). Women receiving CDKI (p = 0.018), without depressive symptomatology (p = 0.043), and with more positive beliefs about medicines were more adherent (p < 0.05). This study enhances understanding of medication adherence in advanced breast cancer and identifies influential factors.

坚持治疗对于晚期乳腺癌患者获得最佳治疗效果至关重要,但由于各种因素,如患者在确诊时的态度和行为以及不良反应率较高的复杂疗法,坚持治疗可能具有挑战性。我们的目的是探讨晚期乳腺癌女性患者口服抗癌药物(OAM)的依从性,重点是细胞周期蛋白依赖性激酶 4 和 6 抑制剂(CDKI),并找出与依从性相关的因素。我们在克罗地亚萨格勒布大学医院中心开展了一项横断面研究,研究对象是接受 OAM 治疗的 IV 期晚期乳腺癌妇女。数据收集包括一份评估社会人口学和临床信息的问卷、针对抑郁症状的贝克抑郁量表-II、针对OAM依从性的用药依从性报告量表(MARS-5)以及药物信念问卷。通过 LC-MS/MS 对随机抽取的三名参与者的血浆 CDKI 浓度进行了确认。共纳入 89 名妇女。处方最多的 OAMs 是抗雌激素(71.3%)和 CDKI(60.9%)。MARS-5 评分(平均值:24.1 ± 1.6)与 CDKI 血浆浓度相关。健忘是不坚持治疗的主要原因(25.9%)。接受 CDKI 治疗(p = 0.018)、无抑郁症状(p = 0.043)、对药物有更积极看法的女性更能坚持用药(p < 0.05)。这项研究加深了人们对晚期乳腺癌患者服药依从性的了解,并找出了影响因素。
{"title":"Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors.","authors":"Matea Baković, Martina Bago, Lucija Benić, Magdalena Krajinović, Tajana Silovski, Natalija Dedić Plavetić, Lu Turković, Miranda Sertić, Maja Ortner Hadžiabdić","doi":"10.2478/acph-2023-0045","DOIUrl":"10.2478/acph-2023-0045","url":null,"abstract":"<p><p>Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, <i>i.e</i>. patients' attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to explore the adherence to oral anticancer medications (OAM) in women with advanced breast cancer, focusing on cyclin-dependent kinase 4 and 6 inhibitors (CDKI), and identify factors associated with the adherence. We conducted a cross-sectional study at the University Hospital Centre Zagreb, Croatia, involving women with stage IV advanced breast cancer receiving OAM. Data collection included a questionnaire assessing socio-demographic and clinical information, Beck Depression Inventory-II for depressive symptoms, Medication Adherence Report Scale (MARS-5) for adherence to OAM, and Beliefs about Medicines Questionnaire. Plasma concentrations of CDKI were confirmed by LC-MS/MS in three randomly selected participants. A total of 89 women were included. The most prescribed OAMs were anti-estrogen (71.3 %) and CDKI (60.9 %). MARS-5 scores (mean: 24.1 ± 1.6) correlated with CDKI plasma concentrations. Forgetfulness was the primary reason for non-adherence (25.9 %). Women receiving CDKI (<i>p</i> = 0.018), without depressive symptomatology (<i>p</i> = 0.043), and with more positive beliefs about medicines were more adherent (<i>p</i> < 0.05). This study enhances understanding of medication adherence in advanced breast cancer and identifies influential factors.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"633-654"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation of astaxanthin/zeaxanthin-loaded nanostructured lipid carriers for enhanced bioavailability: Characterization-, stability-and permeability study. 制备虾青素/玉米黄质纳米结构脂质载体以提高生物利用度:特性、稳定性和渗透性研究。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0038
Kristina Radić, Ana Isabel Barbosa, Salette Reis, Marijan Marijan, Sofia Antunes Costa Lima, Dubravka Vitali Čepo

Astaxanthin (ASTA) and zeaxanthin (ZEA) are xanthophyll carotenoids showing a wide spectrum of health-promoting properties. However, their utilization is limited, mostly due to poor water solubility, limited bioavailability, and a tendency to oxidate, as well as photo- and thermal instability. The aim of this work was to develop ASTA- and ZEA-loaded nano-structured lipid carriers (NLCs) that would protect them against degradation and improve their intestinal stability/permeability. Obtained NLCs were characterized by an effective diameter of 294 nm for ASTA-NLC and 280 nm for ZEA-NLC; polydispersity index (PDI) lower than 0.2; and zeta potential of -29.4 mV and -29.0 mV, respectively. Interestingly, despite similar physicochemical characteristics, our investigation revealed differences in the encapsulation efficiency of ASTA-NLC and ZEA-NLC (58.0 % vs. 75.5 %, respectively). Obtained NLCs were stable during a 21 day-storage period in the dark at room temperature or at 4 °C. Investigation of gastrointestinal stability showed no change in effective diameter and PDI under gastric conditions while both parameters significantly changed under intestinal conditions. Our results showed for the first time that both ASTA- and ZEA-NLCs intestinal absorption investigated in the in vitro model is significantly increased (in relation to pure compounds) and is affected by the presence of mucus. This study provides useful data about the advantages of using NLC as a delivery system for ASTA and ZEA that might facilitate their applications in the food and pharmaceutical industry.

虾青素(ASTA)和玉米黄质(ZEA)是类黄素胡萝卜素,具有广泛的促进健康的特性。然而,它们的利用率有限,主要原因是水溶性差、生物利用率有限、易氧化以及光热不稳定性。这项工作的目的是开发载入 ASTA 和 ZEA 的纳米结构脂质载体(NLCs),以防止它们降解并提高其肠道稳定性/渗透性。获得的 NLC 的特征是:ASTA-NLC 的有效直径为 294 nm,ZEA-NLC 的有效直径为 280 nm;多分散指数(PDI)低于 0.2;ZETA 电位分别为 -29.4 mV 和 -29.0 mV。有趣的是,尽管理化特性相似,但我们的研究发现 ASTA-NLC 和 ZEA-NLC 的封装效率存在差异(分别为 58.0% 和 75.5%)。获得的 NLC 在室温或 4 °C 黑暗环境中储存 21 天后保持稳定。胃肠道稳定性调查显示,有效直径和 PDI 在胃部条件下没有变化,而在肠道条件下这两个参数都发生了显著变化。我们的研究结果首次表明,在体外模型中研究的 ASTA 和 ZEA-NLCs 的肠道吸收率都明显增加(与纯化合物相比),并受到粘液存在的影响。这项研究提供了有关使用 NLC 作为 ASTA 和 ZEA 输送系统的优势的有用数据,这可能会促进它们在食品和制药行业的应用。
{"title":"Preparation of astaxanthin/zeaxanthin-loaded nanostructured lipid carriers for enhanced bioavailability: Characterization-, stability-and permeability study.","authors":"Kristina Radić, Ana Isabel Barbosa, Salette Reis, Marijan Marijan, Sofia Antunes Costa Lima, Dubravka Vitali Čepo","doi":"10.2478/acph-2023-0038","DOIUrl":"10.2478/acph-2023-0038","url":null,"abstract":"<p><p>Astaxanthin (ASTA) and zeaxanthin (ZEA) are xanthophyll carotenoids showing a wide spectrum of health-promoting properties. However, their utilization is limited, mostly due to poor water solubility, limited bioavailability, and a tendency to oxidate, as well as photo- and thermal instability. The aim of this work was to develop ASTA- and ZEA-loaded nano-structured lipid carriers (NLCs) that would protect them against degradation and improve their intestinal stability/permeability. Obtained NLCs were characterized by an effective diameter of 294 nm for ASTA-NLC and 280 nm for ZEA-NLC; polydispersity index (<i>PDI</i>) lower than 0.2; and zeta potential of -29.4 mV and -29.0 mV, respectively. Interestingly, despite similar physicochemical characteristics, our investigation revealed differences in the encapsulation efficiency of ASTA-NLC and ZEA-NLC (58.0 % <i>vs</i>. 75.5 %, respectively). Obtained NLCs were stable during a 21 day-storage period in the dark at room temperature or at 4 °C. Investigation of gastrointestinal stability showed no change in effective diameter and <i>PDI</i> under gastric conditions while both parameters significantly changed under intestinal conditions. Our results showed for the first time that both ASTA- and ZEA-NLCs intestinal absorption investigated in the <i>in vitro</i> model is significantly increased (in relation to pure compounds) and is affected by the presence of mucus. This study provides useful data about the advantages of using NLC as a delivery system for ASTA and ZEA that might facilitate their applications in the food and pharmaceutical industry.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"581-599"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prescribers' approval rate of pharmacist-initiated interventions to optimise patients' clinical status of hypertension in the ambulatory care setting. 处方者对药剂师发起的干预措施的认可率,以优化门诊护理环境中患者的高血压临床状态。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0047
Andrea Brajković, Lucija Ana Bićanić, Helena Orehovački, Ingrid Prkačin, Djenane Ramalho De Oliveira, Iva Mucalo

This perspective, pre- and post-intervention study with a one-year follow-up primarily aimed to ascertain prescribers' approval rate of pharmacists' interventions and clinical status of hypertension following comprehensive medication management (CMM) intervention in the ambulatory care clinic. Between January 2018 and January 2022 overall 100 patients with hypertension and other comorbidities were referred to the CMM services at the Health Centre Zagreb - Centar (HCZC). Out of 275 interventions directed to prescribers, 73.1 % of interventions were approved, 12.4 % were rejected and 14.5 % were not reviewed. The percentage of patients with a blood pressure goal increased from 45 % at the initial consultation to 82.5 % at the patients' latest encounter (p < 0.001). The average number of drug therapy problems (DTPs) per patient totaled 3.53 ± 1.80, where 98 % of patients had one or more DTPs, 48 % had 4 or more DTPs, whereas 26 % had 5 or more DTPs. Sub-therapeutic dosage (32.6 %) and the need for additional drug therapy (30.9 %) were the two most commonly identified DTPs. These results reinforce the need to integrate pharmacy-led services in the primary care setting with the aim of improving patients' health outcomes.

这项为期一年的干预前后透视研究的主要目的是确定处方者对药剂师干预措施的认可率,以及在非住院医疗诊所进行综合用药管理(CMM)干预后的高血压临床状态。2018年1月至2022年1月期间,共有100名高血压和其他合并症患者转诊至萨格勒布健康中心(Health Centre Zagreb - Centar,HCZC)的CMM服务机构。在向处方者提供的 275 项干预措施中,73.1% 的干预措施获得批准,12.4% 遭到拒绝,14.5% 未经审查。有血压目标的患者比例从初诊时的 45% 增加到最近一次就诊时的 82.5%(p < 0.001)。每位患者的平均药物治疗问题(DTPs)总数为 3.53 ± 1.80,其中 98% 的患者有一个或多个 DTPs,48% 的患者有 4 个或多个 DTPs,而 26% 的患者有 5 个或多个 DTPs。治疗剂量不足(32.6%)和需要额外药物治疗(30.9%)是最常见的两种 DTP。这些结果进一步说明,有必要将药学主导的服务整合到基层医疗机构中,以改善患者的健康状况。
{"title":"Prescribers' approval rate of pharmacist-initiated interventions to optimise patients' clinical status of hypertension in the ambulatory care setting.","authors":"Andrea Brajković, Lucija Ana Bićanić, Helena Orehovački, Ingrid Prkačin, Djenane Ramalho De Oliveira, Iva Mucalo","doi":"10.2478/acph-2023-0047","DOIUrl":"10.2478/acph-2023-0047","url":null,"abstract":"<p><p>This perspective, pre- and post-intervention study with a one-year follow-up primarily aimed to ascertain prescribers' approval rate of pharmacists' interventions and clinical status of hypertension following comprehensive medication management (CMM) intervention in the ambulatory care clinic. Between January 2018 and January 2022 overall 100 patients with hypertension and other comorbidities were referred to the CMM services at the Health Centre Zagreb - Centar (HCZC). Out of 275 interventions directed to prescribers, 73.1 % of interventions were approved, 12.4 % were rejected and 14.5 % were not reviewed. The percentage of patients with a blood pressure goal increased from 45 % at the initial consultation to 82.5 % at the patients' latest encounter (<i>p</i> < 0.001). The average number of drug therapy problems (DTPs) per patient totaled 3.53 ± 1.80, where 98 % of patients had one or more DTPs, 48 % had 4 or more DTPs, whereas 26 % had 5 or more DTPs. Sub-therapeutic dosage (32.6 %) and the need for additional drug therapy (30.9 %) were the two most commonly identified DTPs. These results reinforce the need to integrate pharmacy-led services in the primary care setting with the aim of improving patients' health outcomes.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"723-734"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simultaneous determination of macrolides in water samples by solid-phase extraction and capillary electrophoresis. 利用固相萃取和毛细管电泳同时测定水样中的大环内酯类化合物。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI: 10.2478/acph-2023-0041
Dragana Mutavdžić Pavlović, Sandra Babić, Mirta Čizmić, Miranda Sertić, Tea Pinušić

Solid-phase extraction (SPE) coupled with capillary electrophoresis (CE) for the determination of macrolide antibiotics (azithromycin, clarithromycin, roxithromycin, tylosin) and tiamulin in water samples was described in this article. These compounds were extracted with different types of sorbents ( Oasis HLB, C18, C8, SDB, and Strata-X) and different masses of sorbents (60 mg, 200 mg, and 500 mg) using different organic solvents (methanol, ethanol, and acetonitrile) and different pH values of water samples (pH 7.00, 8.00, and 9.00). It was found that the highest extraction efficiency of the studied compounds was obtained with 200 mg/3 mL C18 cartridges with methanol as eluent at pH 9.00 of the water sample. The developed SPE-CE method for macrolide antibiotics and tiamulin was validated for linearity, precision, repeatability, the limit of detection (LOD), the limit of quantification (LOQ), and recovery. Good linearity was obtained in the range of 0.3-30 mg L-1 depending on the drug, with correlation coefficients higher than 0.9958 in all cases except clarithromycin (0.9873). Expanded measurement uncertainties were calculated for each pharmaceutical, accounting for 20.31 % (azithromycin), 38.33 % (tiamulin), 28.95 % (clarithromycin), 26.99 % (roxithromycin), and 21.09 % (tiamulin). Uncertainties associated with precision and calibration curves contributed the most to the combined measurement uncertainty. The method was successfully applied to the analysis of production waste-water from the pharmaceutical industry.

本文介绍了固相萃取(SPE)结合毛细管电泳(CE)测定水样中大环内酯类抗生素(阿奇霉素、克拉霉素、罗红霉素、泰乐菌素)和替莫林的方法。采用不同类型的吸附剂(Oasis HLB、C18、C8、SDB 和 Strata-X)和不同质量的吸附剂(60 毫克、200 毫克和 500 毫克),使用不同的有机溶剂(甲醇、乙醇和乙腈)和不同的水样 pH 值(pH 7.00、8.00 和 9.00)对这些化合物进行了萃取。结果表明,在水样 pH 值为 9.00 时,使用 200 mg/3 mL C18 滤芯,以甲醇为洗脱剂,对所研究化合物的萃取效率最高。所建立的大环内酯类抗生素和替莫林的 SPE-CE 方法在线性、精密度、重复性、检出限(LOD)、定量限(LOQ)和回收率方面均得到了验证。根据药物的不同,在 0.3-30 mg L-1 的范围内线性关系良好,除克拉霉素(0.9873)外,相关系数均高于 0.9958。计算出每种药物的扩展测量不确定度分别为 20.31 %(阿奇霉素)、38.33 %(替米考林)、28.95 %(克拉霉素)、26.99 %(罗红霉素)和 21.09 %(替米考林)。与精密度和校准曲线相关的不确定性对综合测量不确定性的影响最大。该方法成功地应用于制药行业生产废水的分析。
{"title":"Simultaneous determination of macrolides in water samples by solid-phase extraction and capillary electrophoresis.","authors":"Dragana Mutavdžić Pavlović, Sandra Babić, Mirta Čizmić, Miranda Sertić, Tea Pinušić","doi":"10.2478/acph-2023-0041","DOIUrl":"10.2478/acph-2023-0041","url":null,"abstract":"<p><p>Solid-phase extraction (SPE) coupled with capillary electrophoresis (CE) for the determination of macrolide antibiotics (azithromycin, clarithromycin, roxithromycin, tylosin) and tiamulin in water samples was described in this article. These compounds were extracted with different types of sorbents ( Oasis HLB, C18, C8, SDB, and Strata-X) and different masses of sorbents (60 mg, 200 mg, and 500 mg) using different organic solvents (methanol, ethanol, and acetonitrile) and different pH values of water samples (pH 7.00, 8.00, and 9.00). It was found that the highest extraction efficiency of the studied compounds was obtained with 200 mg/3 mL C18 cartridges with methanol as eluent at pH 9.00 of the water sample. The developed SPE-CE method for macrolide antibiotics and tiamulin was validated for linearity, precision, repeatability, the limit of detection (<i>LOD</i>), the limit of quantification (<i>LOQ</i>), and recovery. Good linearity was obtained in the range of 0.3-30 mg L<sup>-1</sup> depending on the drug, with correlation coefficients higher than 0.9958 in all cases except clarithromycin (0.9873). Expanded measurement uncertainties were calculated for each pharmaceutical, accounting for 20.31 % (azithromycin), 38.33 % (tiamulin), 28.95 % (clarithromycin), 26.99 % (roxithromycin), and 21.09 % (tiamulin). Uncertainties associated with precision and calibration curves contributed the most to the combined measurement uncertainty. The method was successfully applied to the analysis of production waste-water from the pharmaceutical industry.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"515-535"},"PeriodicalIF":2.8,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xanthoxyletin blocks the RANK/RANKL signaling pathway to suppress the growth of human pancreatic cancer cells. 黄酮素能阻断 RANK/RANKL 信号通路,从而抑制人类胰腺癌细胞的生长。
IF 2.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-09-14 Print Date: 2023-09-01 DOI: 10.2478/acph-2023-0024
Xin Zhang, Luming Li, Yan Wu

Xanthoxyletin is a vital plant-derived bioactive coumarin. It has been shown to exhibit anticancer effects against different human cancers. Nonetheless, the anticancer effects of xanthoxyletin against human pancreatic cancer cells have not been evaluated. Against this backdrop, the present study was designed to evaluate the anticancer effects of xanthoxyletin in human pancreatic cancer cells and to decipher the underlying molecular mechanisms. The results revealed a significant (p < 0.05) upregulation of receptor activator of NF-kappaB (RANK), receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in human pancreatic tissues and cell lines at both transcriptional and translational levels. The administration of pancreatic cancer cells with xanthoxyletin diminished the viability of Capan-2 cells in a concentration-dependent manner and led to a significant decline in RANK, RANKL, and OPG expression. Silencing of RANK and xanthoxyletin treatment declined the viability of Capan-2 pancreatic cancer cells via induction of apoptosis. However, pancreatic cancer cells overexpressing RANK could rescue the growth inhibitory effects. Collectively, xanthoxyletin targets the RANK/RANKL signaling pathway in pancreatic cancer cells to induce cell apoptosis and may prove to be an important lead molecule.

黄腐素是一种重要的植物源生物活性香豆素。它已被证明对不同的人类癌症具有抗癌作用。然而,黄藤素对人类胰腺癌细胞的抗癌作用尚未得到评估。在此背景下,本研究旨在评估黄藤素对人类胰腺癌细胞的抗癌作用,并破译其潜在的分子机制。结果显示,在人胰腺组织和细胞系中,NF-kappaB受体激活因子(RANK)、NF-kappaB受体激活因子配体(RANKL)和骨保护素(OPG)在转录和翻译水平上都有明显的上调(p < 0.05)。给胰腺癌细胞施用黄腐素,会以浓度依赖的方式降低Capan-2细胞的活力,并导致RANK、RANKL和OPG的表达显著下降。通过诱导细胞凋亡,RANK 沉默和黄腐酸处理降低了 Capan-2 胰腺癌细胞的存活率。然而,过表达 RANK 的胰腺癌细胞可以挽救生长抑制作用。总之,黄腐素可靶向胰腺癌细胞的 RANK/RANKL 信号通路诱导细胞凋亡,可能被证明是一种重要的先导分子。
{"title":"Xanthoxyletin blocks the RANK/RANKL signaling pathway to suppress the growth of human pancreatic cancer cells.","authors":"Xin Zhang, Luming Li, Yan Wu","doi":"10.2478/acph-2023-0024","DOIUrl":"10.2478/acph-2023-0024","url":null,"abstract":"<p><p>Xanthoxyletin is a vital plant-derived bioactive coumarin. It has been shown to exhibit anticancer effects against different human cancers. Nonetheless, the anticancer effects of xanthoxyletin against human pancreatic cancer cells have not been evaluated. Against this backdrop, the present study was designed to evaluate the anticancer effects of xanthoxyletin in human pancreatic cancer cells and to decipher the underlying molecular mechanisms. The results revealed a significant (<i>p</i> < 0.05) upregulation of receptor activator of NF-kappaB (RANK), receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in human pancreatic tissues and cell lines at both transcriptional and translational levels. The administration of pancreatic cancer cells with xanthoxyletin diminished the viability of Capan-2 cells in a concentration-dependent manner and led to a significant decline in RANK, RANKL, and OPG expression. Silencing of RANK and xanthoxyletin treatment declined the viability of Capan-2 pancreatic cancer cells <i>via</i> induction of apoptosis. However, pancreatic cancer cells overexpressing RANK could rescue the growth inhibitory effects. Collectively, xanthoxyletin targets the RANK/RANKL signaling pathway in pancreatic cancer cells to induce cell apoptosis and may prove to be an important lead molecule.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 3","pages":"503-513"},"PeriodicalIF":2.8,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10287720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Pharmaceutica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1